Real-time insights. Smarter decisions. Better trades.
🔍 Search StocksConfidence: 65%
Date: 15-05-2026
Price: $1.160
Last Price: $1.045
Post-Signal Peak Price: $1.060
PolyNovo (ASX:PNV) has appointed Robert Douglas to its Board of Directors, a move that brings decades of international medical device leadership into the mix. Investors are tuning in to see what his experience could mean for PolyNovo’s strategic direction. See our latest analysis for PolyNovo. Pol
PolyNovo Limited recently appointed Mr. Robert Douglas to its Board of Directors, bringing over thirty-five years of experience in medical device technology, digital health, and public company governance, with senior leadership roles at ResMed and board responsibilities at Globus Medical. This appoi
While PolyNovo Limited (ASX:PNV) might not have the largest market cap around , it saw a significant share price rise of 55% in the past couple of months on the ASX. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. As a s
Key Insights Using the 2 Stage Free Cash Flow to Equity, PolyNovo fair value estimate is AU$2.95 Current share price of AU$1.55 suggests PolyNovo is potentially 48% undervalued The AU$1.81 analyst price target for PNV is 39% less than our estimate of fair value Does the December share price for Po
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But when you pick a company that is really flourishing, you can make more than 100%. One great example is PolyNovo Limited (ASX:PNV) which saw its share price drive 162% hi
Chart available once enough post-signal price data is available.
AI Confidence - 65 % model confidence
Polynovo Limited is a medical device company specializing in the development and commercialization of innovative wound care and regenerative products, primarily its NovoSorb biodegradable polymer technology. The company holds a strong position in the advanced wound care market with growing international presence and partnerships, targeting chronic wounds and surgical applications.
| Cash Flow | Moderate |
| Debt | Low |
| Profitability | Moderate |
| Revenue Trend | Uptrend |
| Trend | Bullish |
| Momentum | Moderate |
| RSI Signal | Neutral |
| Support Level | $ 1.00 |
| Resistance Level | $ 1.30 |